2019 Leads Pharmacology 
European Pharmaceutical Review
APRIL 10, 2025
Key findings for UK clinical trials For clinical trials submitted between 2019 and 2023, highlights from the analysis showed that one in eight trials tested treatments in humans for the first time.
European Pharmaceutical Review
AUGUST 23, 2022
The researchers studied 254 VA patients who were diagnosed with PTSD and hepatitis C between October 1999 and September 2019. PTSD is a potentially chronic condition that disrupts lives and can lead to or exacerbate existing health issues such as depression, anxiety, eating disorders, and suicidal thoughts.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
FEBRUARY 8, 2023
Blank acknowledged that in many cases, an exclusively paediatric patient population could lead to difficulties with drawing consent for early phase trials. Still, Blank suggested that companies enroll the patient population that is most likely to benefit, because early phase studies contain the most safety risks.
European Pharmaceutical Review
DECEMBER 11, 2023
Known linkers in the RNA field are used to bond together the two pharmacologically active molecular entities and can be applied to multiple oligonucleotide modalities. Research advances are also helping us learn more about how RNA is processed, potentially leading to new strategies to alter dysfunctional RNA. 2019 ;42:385-406.
Pharmaceutical Representative Training
JANUARY 30, 2025
Therapeutic drug monitoring is used to obtain peak and trough levels to determine drug serum concentration which tells us if a drug is efficacious or is leading to toxic levels. warfarin) which leads to higher plasma concentrations. Rang & Dale’s Pharmacology. The Pharmacological Basis of Therapeutics.
Legacy MEDSearch
AUGUST 25, 2022
Early non-randomized European studies have suggested that this leads to reduced incidence of coronary microvascular obstruction (MVO) [3,4] and smaller infarct size, which are both strongly correlated to improvement in heart failure hospitalizations and reduced mortality following primary PCI [5]. About Miracor Medical.
European Pharmaceutical Review
JANUARY 13, 2025
Research demonstrates that the greenest inhaler is the one that is used and that leads to disease control. If we want to lead the way in green innovation and show that the UK is open for business, we need a broader definition and recognition of innovation. Pulmonary Pharmacology & Therapeutics. 2024; 85: 1-9.
Expert insights. Personalized for you.
52 
Let's personalize your content